Discovery of the biomarker belonging to the SLC45A2 gene.
Technical development of the Melapred test.
Creation of the Genepredict Company and incubated at the Paris Biotech Santé Group.
Financial aid from BPI (PIA) (Investment bank).
Financial support by the Business Angels in Reims.
Completion of Melapred pilot study.
Signing of the licence agreement with AP-HP (Assistance Publique/Hôpitaux de Paris).
Launch of the development of new predisposition tests.
CE marking granted, and hearing by the ANSM.
Genepredict.fr website published online.
Marketing launch of the Melapred test.
Appointment of a CE0.